Simnikiwe H. Mayaphi

Prof. Simnikiwe H. Mayaphi

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2015 in Journal of Clinical Virology
Verified
Journal Article
Closed access
EAEdina Amponsah-Dacosta
Edina Amponsah-Dacosta
Ramokone Lisbeth LebeloRamokone Lisbeth Lebelo
Ramokone Lisbeth Lebelo
JRJ. Nare Rakgole
J. Nare Rakgole
GSGloria Selabe
Gloria Selabe
MGMaemu P. Gededzha
Maemu P. Gededzha
MMM. Jeffrey Mphahlele
M. Jeffrey Mphahlele

23 February 2012 in South African Medical Journal
Verified
Journal Article
Open access
PDF file
SMSimnikiwe H. Mayaphi
Simnikiwe H. Mayaphi
TRTheresa M Roussow
Theresa M Roussow
DMDifuro P Masemola
Difuro P Masemola
SOSteve A S Olorunju
Steve A S Olorunju
MMM Jeffrey Mphahlele
M Jeffrey Mphahlele
DMDesmond J Martin
Desmond J Martin
HBV/HIV co-infection: The dynamics of HBV in South African patients with AIDS

1 April 2013 in Journal of Virological Methods
Verified
Journal Article
Closed access
MBMarieke Brauer
Marieke Brauer
JVJohanna C. De Villiers
Johanna C. De Villiers
SMSimnikiwe H. Mayaphi
Simnikiwe H. Mayaphi

3 April 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SMSimnikiwe H. Mayaphi
Simnikiwe H. Mayaphi
MBMarieke Brauer
Marieke Brauer
DMDaniel M. Morobadi
Daniel M. Morobadi
AMAhmad H. Mazanderani
Ahmad H. Mazanderani
RMRendani T. Mafuyeka
Rendani T. Mafuyeka
ASAnton Stoltz
Anton Stoltz
Cytomegalovirus (CMV) infection is associated with severe diseases in immunosuppressed patients; however, there is a lack of data for pre-emptive therapy in patients with HIV/AIDS. This was a retrospective study, which enrolled patients diagnosed with HIV/AIDS (CD41,000 copies/ml at baseline testing had significantly higher mortality compared to those who had 5,100 copies/ml and did not receive ganciclovir had 100% mortality compared to 58% mortality in those who received ganciclovir at VLs of >5,100 copies/ml, 50% mortality in those who were not treated and had low VLs of <5,100 copies/ml, and 44% mortality in those who had ganciclovir treatment at VLs of <5,100 copies/ml (p = 0.084, 0.046, 0.037, respectively). This study showed a significantly increased mortality in patients with HIV/AIDS who had high CMV VLs, and suggests that a threshold value of 1,000 copies/ml may be appropriate for pre-emptive treatment in this group.

20 October 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SMSimnikiwe H. Mayaphi
Simnikiwe H. Mayaphi
DMDesmond J. Martin
Desmond J. Martin
TQThomas C. Quinn
Thomas C. Quinn
OLOliver Laeyendecker
Oliver Laeyendecker
SOSteve A. S. Olorunju
Steve A. S. Olorunju
ASAnton C. Stoltz
Anton C. Stoltz
Two thirds of the world’s new HIV infections are in sub-Saharan Africa. Acute HIV infection (AHI) is the time of virus acquisition until the appearance of HIV antibodies. Early HIV infection, which includes AHI, is the interval between virus acquisition and establishment of viral load set-point. This study aimed to detect acute and early HIV infections in a hyper-endemic setting. This was a cross-sectional diagnostic study that enrolled individuals who had negative rapid HIV results in five clinics in South Africa. Pooled nucleic acid amplification testing (NAAT) was performed, followed by individual sample testing in positive pools. NAAT-positive participants were recalled to the clinics for confirmatory testing and appropriate management. HIV antibody, p24 antigen, Western Blot and avidity tests were performed for characterization of NAAT-positive samples. The study enrolled 6910 individuals with negative rapid HIV results. Median age was 27 years (interquartile range {IQR}: 23–31). NAAT was positive in 55 samples, resulting in 0.8% newly diagnosed HIV-infected individuals (95% confidence interval {CI}: 0.6–1.0). The negative predictive value for rapid HIV testing was 99.2% (95% CI: 99.0–99.4). Characterization of NAAT-positive samples revealed that 0.04% (95% CI: 0.000–0.001) had AHI, 0.3% (95% CI: 0.1–0.4) had early HIV infection, and 0.5% (95% CI: 0.5–0.7) had chronic HIV infection. Forty-seven (86%) of NAAT-positive participants returned for follow-up at a median of 4 weeks (IQR: 2–8). Follow-up rapid tests were positive in 96% of these participants. NAAT demonstrated that a substantial number of HIV-infected individuals are misdiagnosed at South African points-of-care. Follow-up rapid tests done within a 4 week interval detected early and chronic HIV infections initially missed by rapid HIV testing. This may be a practical and affordable strategy for earlier detection of these infections in resource-constrained settings. Newer molecular tests that can be used at the points-of-care should be evaluated for routine diagnosis of HIV in hyper-endemic settings.

5 June 2015 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
PDF file
ABAné Büchner
Ané Büchner
NPNelita du Plessis
Nelita du Plessis
DRDavid T. Reynders
David T. Reynders
FOFareed E. Omar
Fareed E. Omar
SMSimnikiwe H. Mayaphi
Simnikiwe H. Mayaphi
TATheunis Avenant
Theunis Avenant
Background: Hospital‐acquired hepatitis B virus (HBV) infection has been well described and continues to occur worldwide. Recent nosocomial outbreaks have been linked to unsafe injection practices, use of multi‐dose vials, and poor staff compliance with standard precautions. This report describes a nosocomial outbreak that occurred in a pediatric hematology and oncology unit of a large academic hospital, the epidemiological investigation of the outbreak, and preventive measures implemented to limit further in‐hospital transmission.Methods: Outbreak investigation including contact tracing and HBV screening were initially carried out on all patients seen by the unit during the same period as the first three cases. Routine screening for the entire patient population of the unit was initiated in February 2013 when it was realized that numerous patients may have been exposed.Results: Forty‐nine cases of HBV infection were confirmed in 408 patients tested between July 2011 and October 2013. Phylogenetic analysis of the HBV preC/C gene nucleotide sequences revealed that all tested outbreak strains clustered together. Most (67%) patients were HBeAg positive. The cause of transmission could not be established. Preventive measures targeted three proposed routes. HBV screening and vaccination protocols were started in the unit.Conclusions: The high number of HBeAg positive patients, together with suspected lapses in infection prevention and control measures, are believed to have played a major role in the transmission. Measures implemented to prevent further in‐hospital transmission were successful. On‐going HBV screening and vaccination programs in pediatric hematology and oncology units should become standard of care. Pediatr Blood Cancer